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Abstract
Background—Multiple studies demonstrate poor adherence to medications prescribed for
chronic illnesses, including osteoporosis, but few interventions have been proven to enhance
adherence. We examined the effectiveness of a telephone-based counseling program rooted in
motivational interviewing to improve medication adherence for osteoporosis.
Methods—We conducted a one year randomized controlled clinical trial. Participants were
recruited from a large pharmacy benefits program for Medicare beneficiaries. All potentially
eligible individuals had been newly prescribed a medication for osteoporosis. Consenting persons
were randomized to either a program of telephone-based counseling (n = 1,046) using a
motivational interviewing framework or a control group (n = 1,041) that received mailed
educational materials. Medication adherence was the primary outcome compared across treatment
arms and was measured as the median (interquartile range, IQR) medication possession ratio
(MPR), calculated as the ratio of days with filled prescriptions to total days of follow-up.
Results—The groups were balanced at baseline, with a mean age of 78 years; 94% were female.
In an intention-to-treat analysis, median adherence was 49% (IQR 7, 88) in the intervention arm
and 41% (1.5, 86.0) in the control arm (P = 0.074 by Kruskal-Wallis test). There were no
differences in self-reported fractures.
Conclusions—In this randomized controlled trial, we did not find a statistically significant
improvement in osteoporosis medication adherence using a telephonic motivational interviewing
intervention.
INTRODUCTION
Adherence with many chronic medications is poor and appears worse for conditions that do
not produce daily symptoms.1 A meta-analysis involving over 50,000 patients found that
people with osteoporosis adhere to 48% of days with a prescribed treatment during the first
year of therapy.2 More than 2 million fractures associated with osteoporosis or osteopenia
occur annually in the US at an estimated medical cost of $19 billion.3 Medications have
been shown to reduce fracture risk in many populations;4 thus, improving adherence to
osteoporosis regimens is a public health priority.5
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Non-adherence is a complex behavior with many potential causes,6 including concerns
about medication safety, lack of confidence in a medication’s benefits or in the patient’s
ability to adhere, forgetfulness, complexity of treatment regimen and drug affordability.1, 7–9
The multitude of reasons underpinning medication non-adherence, and the failure of many
unidimensional programs suggest that a successful intervention needs to be multi-faceted
and tailored for a given individual.10 These features are characteristic of one-on-one
counseling interventions. Several medication adherence interventions using counseling
based on motivational interviewing have been successful in other clinical areas.11, 12
Motivational interviewing is a client-centered counseling method based on the stages of
change model of health behavior.13, 14 The counselor interacts with the patient to identify
the reasons for problematic health behaviors, and then shapes the counseling to address the
issues most likely to help that particular person. We developed a motivational interviewing
program that could be delivered by health educators via the telephone. Medicare
beneficiaries starting prescription osteoporosis medications were recruited and randomized
to receive either motivational interviewing counseling sessions or mailed educational
materials.
METHODS
Study Design and Oversight
The OPTIMA (Osteoporosis Telephonic Intervention to Improve Medication Adherence)
Trial was a large pragmatic randomized effectiveness trial, which has been described in
detail previously.15 The trial was conducted in accordance with the trial protocol, which was
reviewed by the Partners Healthcare Institutional Review Board. The study was deemed
exempt from Institutional Review Board oversight. However, a safety officer appointed by
the National Institutes of Health (the funding agency) reviewed safety data over the course
of the trial. The study was designed by the authors; data were collected in a blinded fashion
and analyzed by a statistical programmer blinded to treatment assignment. The Principal
Investigator (DHS) vouches for the accuracy and completeness of the data and analysis.
Study Participants
We collaborated with a state-run pharmacy benefits program for low income older adults
residing in the state of Pennsylvania.16 Over 200,000 state residents are enrolled annually
and receive medications for a nominal co-payment. Monthly administrative claims files
identifying beneficiaries starting a prescription medication for osteoporosis (e.g., estrogen
replacement therapy, a bisphosphonate, teriparatide, calcitonin, or raloxifene) were
transferred securely to the study team. Subjects received a letter inviting them to participate
in the program and providing them the opportunity to opt out of further contact. Potentially
eligible subjects who did not opt out were contacted and recruitment was attempted if they
met additional study eligibility criteria, including living in the community, and being able to
understand spoken English. Subjects gave verbal consent to be part of a program for
osteoporosis and were then randomized to the intervention or control arms (see Figure 1).
Since all subjects in both arms received enhanced care, subjects were not aware of their
treatment arm allocation.
Intervention
Approximately 30 days after randomization, all subjects in both arms began to receive
mailings regarding osteoporosis. Over the course of the study, all subjects received seven
informational mailings covering topics such as exercise, fall prevention, and recommended
calcium intake (see Supplemental File for mailings). The subjects in the intervention arm
also received motivational interviewing counseling sessions via telephone with one of seven
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health educators. We aimed for ten counseling sessions per subject over the course of the
study. Each session had a specific educational topic (e.g., discussing medications with your
doctor, calcium and vitamin D supplementation, fall prevention, managing medication side
effects) and included a series of open ended questions to elicit subjects’ attitudes toward
medication adherence and to determine barriers to long-term osteoporosis medication use
The health educators received training in motivational interviewing through a half-day
training program at study initiation, including role-playing, lecture, and discussion. The
motivational interviewing counseling was reinforced through telephone conferences 1–2
times per month with a behavioral scientist and clinical expert. In addition, three times over
the course of the 2.5 years of the study period, health educators recorded client telephone
calls (with subject’s consent) which were then reviewed and graded by a motivational
interviewing trainer. The trainer gave structured feedback to each health educator using an
assessment tool.17
Outcomes
The primary outcome of the study was adherence to prescription osteoporosis medications,
as measured by the medication possession ratio (MPR) during the 12 months of follow-up.18
The MPR can be measured using different methods; we calculated it as:19
We used pharmacy claims data from the collaborating state-run pharmacy benefits program
to calculate the MPR. Paid medication claims based on filled prescriptions form the basis for
these data. The MPR is widely recognized as a valid measure of adherence.18
Secondary outcomes included persistence with prescription osteoporosis medication, defined
as days from initial prescription until the first period in which the subject experienced an
interruption in prescription filling lasting longer than 60 days.18 We also assessed self-
reported fractures, falls, and depression, and satisfaction with the program using an exit
survey.
Statistical analyses
Primary analysis—The analysis was carried out according to a pre-determined statistical
analysis plan. We compared the baseline characteristics of the two treatment arms using the
Student t-test for continuous variables and a Kruskal-Wallis test for categorical items. The
primary analyses of outcomes used an intention to treat approach that evaluated all subjects
in the assigned treatment arms until the completion of the 12 month follow-up period
without regard to drop-out (unless subjects died or lost eligibility for the state-run pharmacy
benefits program, in which case they were censored at the time of these events). The
distribution of MPRs was not normal and thus we compared the median (interquartile range;
IQR) MPR across the two treatment arms. For each treatment arm, we also compared the
distribution of MPRs, calculated as the percentage of patients in each decile of MPR.
The sample size was chosen to ensure 90% power to detect an absolute difference of 10% in
adherence (measured by MPR) between the two arms.
Secondary analyses—We examined the secular trends of MPR by treatment arm across
the study follow-up period, assessing whether the effect of the intervention varied over the
course of the 12 month follow-up period. Follow-up time was partitioned into 60-day
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increments and an interaction term between follow-up time and treatment arm was tested in
a linear regression model, with MPR as the dependent variable.
We also compared the intervention’s effects in subgroups, such as age 65–74 versus 75 and
over, those with a history of a prior fracture versus none, white race versus other, and
married versus not.
During the study period, Medicare Part D was introduced. Some pharmacy claims were
unavailable from Medicare Prescription Drug Plans who did not share complete data with
the state-run pharmacy benefits program. We conducted sensitivity analyses to determine
the potential effects of incomplete data. Subjects were censored when the state-run
pharmacy program noted that a beneficiary entered a “non-participating” Medicare
Prescription Drug Plan.
Persistence with prescription osteoporosis treatments was illustrated using Kaplan-Meier
survival curves and compared across study arms using the log-rank test. The proportions of
subjects in each treatment arm self-reporting fractures, falls, and poor or fair health were
compared using the Kruskal-Wallis test.
The statistical analysis was performed using SAS software, version 9.1.
RESULTS
Patients
We recruited and enrolled 2,097 subjects into the trial (Figure 1). Ten subjects died between
enrollment and the start of follow-up and were excluded, leaving 2,087 for analysis. The
recruited subjects closely resembled the total eligible pool (see Supplemental Table). As
noted in Table 1, the baseline characteristics of subjects in the two arms were similar.
Across both study arms, the mean age was 78 years and 94% were female. Most subjects
were single or widowed. The mean number of comorbid conditions was 5.2 and the mean
number of different medications used in the year prior to the trial was 10.4. Prior fractures,
falls, activity limitations, and poor eyesight were common and similar across treatment
arms. The most common prescription osteoporosis treatment in both arms was weekly
bisphosphonates. The only statistically significant difference across the arms was in the
distribution of races, with slightly more Whites in the intervention arm. Thirty-six subjects
in the intervention and 39 in the control arm died during follow-up.
In the intervention arm, the median number of completed calls was 8 (interquartile range 6
to 9), and the median duration of a counseling session was 14 minutes (interquartile range
10 to 19).
Primary End Point
Over the 12 months of follow-up, the median MPR was 49% (IQR 7–88%) in the
intervention arm and 41% (IQR 1–86%) in the control arm (P from Kruskal-Wallis test =
0.074) (see Table 2). There was a suggestion of difference in MPR between intervention and
control group at the extremes of the distribution: 34% of the intervention groups versus 39%
in the control group had MPR < 20% while 33% in the intervention group versus 30% in the
control group had MPR >80%, but this difference was small and did not reach statistical
significance (P from chi-square trend test across all deciles = 0.078) (see Figure 2). The
trend in the median medication possession ratios for six 60-day intervals during the follow-
up year is shown in Figure 3.
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The sensitivity analyses performed to test the effect of data drop-out through enrollment in
non-participating Medicare Part D Plans showed higher median MPRs for both groups than
in the primary analysis (intervention = 61% and control = 54%).
Secondary End Points
There were no statistically significant differences noted in secondary outcomes, including
self-reported fractures (intervention 11% and control 11%), self-reported falls (intervention
38% and control 36%) or poor or fair general health (intervention 40% and control 41%). In
addition, persistence with osteoporosis medications appeared similar across the two groups
(see Figure 4, log rank p-value 0.34).
Subgroup Analyses
The effectiveness of the intervention appeared to differ modestly across several of the
subgroups (Table 2). The intervention was associated with improvement in MPR for
subjects age 65–74 (median MPR intervention = 48%, compared to MPR control = 31%)
compared to little improvement in those 75 and over (median MPR intervention = 49%,
MPR control = 46%, P for interaction = 0.045). Among those without a prior fracture, the
intervention appeared more effective (median MPR intervention = 50%, MPR control =
35%) compared with those with a prior fracture median (median MPR intervention 46%,
MPR control = 51%, P for interaction = 0.058). As well, the intervention produced
somewhat larger effects among those of White race (median MPR intervention = 50%, MPR
control = 40%) compared with non-Whites (median MPR intervention = 35%, MPR control
= 43%, P for interaction = 0.061). We note that in the latter two subgroup analyses (by prior
fracture history and by race) the interactions terms did not reach statistical significance.
The per patient intervention costs were $280.94, including training of the health educators,
recruitment of subjects, telephone calls, mailings, and data storage.
DISCUSSION
Medication non-adherence results in sub-optimal clinical outcomes and excess health care
costs in many chronic conditions, including osteoporosis.20, 2122, 23 We attempted to
improve prescription medication adherence for osteoporosis through a pragmatic
randomized controlled trial in collaboration with a public prescribing benefits program. The
intervention used principles of motivational interviewing and was delivered by telephone.
Subjects in the intervention arm did not experience a statistically significant increase in
median medication possession ratio, a well accepted measure of adherence,, as compared
with controls.
We used motivational interviewing as the behavioral framework for the medication
adherence counseling. It was carried out by trained health educators who underwent
extensive training, using regular feedback and structured assessments.17 Motivational
interviewing has been widely used for addiction counseling and more recently, has been
adopted for other health care settings.14 It formed the basis for a successful intervention that
improved adherence with anti-hypertensive therapy, improving adherence by 14% and
producing reductions in blood pressure.12 Adherence with anti-retroviral therapy improved
by 4.5% using a motivational interviewing based counseling program.11 However, not all
similar programs have been successful.24 Our intervention was the first telephone-based
motivational interviewing program targeting medication adherence that we are aware of.
Even though our intervention did not achieve a statistically significant improvement, these
prior studies and the effects seen in select prespecified subgroups in our trial suggest that
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motivational interviewing shows promise as a counseling model for medication adherence
and should be investigator further
We had estimated the sample size of this trial based on a 10% increase in medication
adherence, which was deemed to be clinically important. We observed an increase in
adherence of 8%. Thus the trial did not document a statistically significant difference
between randomization groups and did not achieve the clinically important increase in
adherence in adherence we sought to identify. Our follow-up may have been inadequate to
detect a change in fracture rate attributable to a modest change in medication use. We note
that the a priori power calculation for the trial was based on the adherence endpoint and not
the fracture endpoint., as detecting a difference in fractures was unlikely based on our
hypothesized 10% improvement in adherence.23, 25, 26 These findings have several
important implications. First, while our results were not statistically significant, we
demonstrated that a relatively simple intervention has the potential to achieve modest
improvements in medication adherence, particularly in select prespecified subgroups.
Second, the intervention’s structure has relevance for other programs that aim to improve
adherence with recommended regimens. We used health care and pharmacy insurance
claims data to identify people starting a medication for osteoporosis, segment them for
analyses, and collect outcomes data. Since the expansion of Medicare to include drug
benefits, the Center for Medicare and Medicaid Services has the most extensive database of
longitudinal health care utilization on a large portion of the US population. These data
should facilitate case finding and follow-up in care improvement programs as demonstrated
in our intervention trial. Similar capabilities are in place in most large managed care
programs and for most health insurers that cover prescription benefits. This trial also
demonstrates the power of health care and pharmacy insurance claims data to conduct a
large pragmatic trial. We recruited over 2,000 subjects, followed them for a year, and
conducted extensive analyses on a budget of less than one million US dollars (direct costs
over five years). This economy of scale could only be achieved through relying on
administrative data collected as part of routine health care delivery.
The use of routinely collected data presents important methodologic challenges. We relied
on pharmacy claims data to identify recent initiators of an osteoporosis medication. These
data need to be processed and then we allowed potential subjects to opt-out of recruitment.
This meant that by the time subjects were recruited and received their first intervention call,
a median of 113 days had passed since they filled their first prescription. While data shown
in Figure 3 suggest that the intervention’s effect increased over the study period, the lag
period may have limited the benefit of our intervention, since many subjects had already
discontinued use of their osteoporosis medication at the time of their first call (see Figure 4).
If a health care delivery system were to deliver the intervention itself, data would be more
immediately available and lag times would be reduced. In addition, by relying on pharmacy
claims data, we do not know that patients actually took the medicine, only that they filled
prescriptions. Finally, we were only able to enroll a fraction of those who were potentially
eligible. The groups were similar with respect to age, gender, race, and number of
prescription medications (see Supplemental Table).
In conclusion, we conducted a randomized controlled trial of over 2,000 patients that did not
demonstrate a statistically significant improvement in medication adherence associated with
a telephone-based motivational interviewing counseling intervention. Subgroup analyses
suggest that the intervention may be more effective in specific populations including
patients > 75 years old as compared with those 65–74. Further research is necessary to
determine how to best target this intervention. The study also demonstrated the potential
utility of routinely collected prescription data to identify new users of a particular
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medication class and follow them for outcomes. Given the widespread nature of medication
non-adherence, this work may provide useful information for further studies to improve the
appropriateness of prescription drug use.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The CONSORT diagram illustrates the assembly of the study cohort and its follow-up
through the trial procedures. Ten subjects (4 in the intervention arm and 6 in the control
arm) died between recruitment and the start of follow-up 30 days later and were excluded
from analyses.
Solomon et al. Page 9














This histogram displays the distribution of adherence for intervention (white) and control
arm (grey), by decile of medication possession ratio.
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This histogram displays the median medication possession ratios for six 60-day intervals, by
treatment assignment, with intervention in purple and control in red. The interaction effect
between treatment arm and sequential 60-day periods during follow-up was not statistically
significant (P for interaction = 0.60).
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This figure illustrates the persistence over time in use of medications for osteoporosis. The
intervention arm is show in red and the control arm in blue.
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Table 1
Baseline characteristics of study population
Intervention Control
N (%) or mean (± standard deviation)
N 1046 1041
Female gender 986 (94%) 971 (93%)
Age, years* 77.8 (± 6.4) 77.7 (± 6.6)
Race
  White 942 (90%) 909 (87%)
  Non-white 104 (10%) 132 (13%)
Marital status
    Married 228 (22%) 231 (22%)
    Divorced or separated 103 (10%) 124 (12%)
    Widowed or single 715 (68%) 686 (66%)
Number of medications 10.2 (± 6) 10.6 (± 6)
Comorbidities 5.2 (± 3.4) 5.3 (± 3.3)
Prior fracture 303 (30%) 285 (29%)
Poor eyesight 210 (20%) 208 (21%)
Activity limitation 730 (71%) 709 (71%)
Prior falls, at least one 412 (40%) 378 (38%)
Osteoporosis medication
    Bisphosphonate, IV 2 (0.2%) 2 (0.2%)
    Bisphosphonate, oral, daily 7 (0.7%) 4 (0.4%)
    Bisphosphonate, oral, weekly 664 (64%) 666 (64%)
    Other, oral or intranasal 355 (34%) 358 (34%)
    Other, injectable 18 (2%) 11 (1%)
Other osteoporosis medications included raloxifene, calcitonin, teriparatide, and estrogen replacement therapy.
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